Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Stefan WEIDNER, Klaus GOEKE, Uwe TRINKS, Peter TRAXLER, Katharina UCCI-STOLL & Oreste GHISALBA. (1999) Preparation of 4-(4′-Hydroxyanilino)-5-anilinophthalimide and 4,5-Bis-(4′-hydroxyanilino)-phthalimide by Microbial Hydroxylation. Bioscience, Biotechnology, and Biochemistry 63:8, pages 1497-1500.
Read now
Read now
Peter Traxler. (1998) Tyrosine kinase inhibitors in cancer treatment (Part II). Expert Opinion on Therapeutic Patents 8:12, pages 1599-1625.
Read now
Read now
Peter M Traxler. (1997) Protein tyrosine kinase inhibitors in cancer treatment. Expert Opinion on Therapeutic Patents 7:6, pages 571-588.
Read now
Read now
Alexander J Bridges. (1995) Editorial Oncologic, Endocrine & Metabolic: The current status of tyrosine kinase inhibitors: Do the diarylamine inhibitors of the EGF receptor represent a new beginning?. Expert Opinion on Therapeutic Patents 5:12, pages 1245-1257.
Read now
Read now
Articles from other publishers (21)
Tao Peng, Jianfeng Pei & Jiaju Zhou. (2002) 3D-QSAR and Receptor Modeling of Tyrosine Kinase Inhibitors with Flexible Atom Receptor Model (FLARM). Journal of Chemical Information and Computer Sciences 43:1, pages 298-303.
Crossref
Crossref
L. Ramdas, N.U. Obeyesekere, G. Sun, J.S. McMurray & R.J.A. Budde. (1999) N-myristoylation of a peptide substrate for Src converts it into an apparent slow-binding bisubstrate-type inhibitor. The Journal of Peptide Research 53:5, pages 569-577.
Crossref
Crossref
David W. Fry. (1999) Inhibition of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases as an Approach to Cancer Chemotherapy. Pharmacology & Therapeutics 82:2-3, pages 207-218.
Crossref
Crossref
Peter Traxler & Pascal Furet. (1999) Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors. Pharmacology & Therapeutics 82:2-3, pages 195-206.
Crossref
Crossref
Peter Traxler, Jennifer Green, Helmut Mett, Urs Séquin & Pascal Furet. (1999)
Use of a Pharmacophore Model for the Design of EGFR Tyrosine Kinase Inhibitors: Isoflavones and 3-Phenyl-4(1
H
)-quinolones
. Journal of Medicinal Chemistry 42:6, pages 1018-1026.
Crossref
Crossref
David W. Fry, Alexander J. Bridges, William A. Denny, Annette Doherty, Kenneth D. Greis, James L. Hicks, Kenneth E. Hook, Paul R. Keller, Wilbur R. Leopold, Joseph A. Loo, Dennis J. McNamara, James M. Nelson, Veronika Sherwood, Jeff B. Smaill, Susanne Trumpp-Kallmeyer & Ellen M. Dobrusin. (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proceedings of the National Academy of Sciences 95:20, pages 12022-12027.
Crossref
Crossref
Sylvester R. Klutchko, James M. Hamby, Diane H. Boschelli, Zhipei Wu, Alan J. Kraker, Aneesa M. Amar, Brian G. Hartl, Cynthia Shen, Wayne D. Klohs, Randall W. Steinkampf, Denise L. Driscoll, James M. Nelson, William L. Elliott, Billy J. Roberts, Chad L. Stoner, Patrick W. Vincent, Donald J. Dykes, Robert L. Panek, Gina H. Lu, Terry C. Major, Tawny K. Dahring, Hussein Hallak, Laura A. Bradford, H. D. Hollis Showalter & Annette M. Doherty. (1998)
2-Substituted Aminopyrido[2,3-
d
]pyrimidin-7(8
H
)-ones. Structure−Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity
. Journal of Medicinal Chemistry 41:17, pages 3276-3292.
Crossref
Crossref
Klaus Hinterding, Axel Knebel, Peter Herrlich & Herbert Waldmann. (1998) Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry 6:8, pages 1153-1162.
Crossref
Crossref
Vijay R. Baichwal & Patrick A. Baeuerle. 1998.
233
242
.
Peter Traxler, Guido Bold, Joerg Frei, Marc Lang, Nicholas Lydon, Helmut Mett, Elisabeth Buchdunger, Thomas Meyer, Marcel Mueller & Pascal Furet. (1997)
Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-
d
]pyrimidines
. Journal of Medicinal Chemistry 40:22, pages 3601-3616.
Crossref
Crossref
H.D. Hollis Showalter & Alan J. Kraker. (1997) Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases. Pharmacology & Therapeutics 76:1-3, pages 55-71.
Crossref
Crossref
David W Fry, James M Nelson, Veronika Slintak, Paul R Keller, Gordon W Rewcastle, William A Denny, Hairong Zhou & Alexander J Bridges. (1997) Biochemical and antiproliferative properties of 4-[Ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochemical Pharmacology 54:8, pages 877-887.
Crossref
Crossref
Herbert Waldmann, Klaus Hinterding, Peter Herrlich, Hans Jobst Rahmsdorf & Axel Knebel. (2003) Selective Inhibition of Receptor Tyrosine Kinases by Synthetic Analogues of Aeroplysinin. Angewandte Chemie International Edition in English 36:13-14, pages 1541-1542.
Crossref
Crossref
Herbert Waldmann, Klaus Hinterding, Peter Herrlich, Hans Jobst Rahmsdorf & Axel Knebel. (2006) Selektive Inhibierung von Rezeptor‐Tyrosinkinasen mit Aeroplysinin‐Analoga. Angewandte Chemie 109:13-14, pages 1553-1555.
Crossref
Crossref
James M. Hamby, Cleo J. C. Connolly, Mel C. Schroeder, R. Thomas Winters, H. D. Hollis Showalter, Robert L. Panek, Terry C. Major, Bronislawa Olsewski, Michael J. Ryan, Tawny Dahring, Gina H. Lu, Joan Keiser, Aneesa Amar, Cindy Shen, Alan J. Kraker, Veronika Slintak, James M. Nelson, David W. Fry, Laura Bradford, Hussein Hallak & Annette M. Doherty. (1997)
Structure−Activity Relationships for a Novel Series of Pyrido[2,3-
d
]pyrimidine Tyrosine Kinase Inhibitors
. Journal of Medicinal Chemistry 40:15, pages 2296-2303.
Crossref
Crossref
H. D. Hollis Showalter, Anthony D. Sercel, Boguslawa M. Leja, Craig D. Wolfangel, Linda A. Ambroso, William L. Elliott, David W. Fry, Alan J. Kraker, Curtis T. Howard, Gina H. Lu, Charles W. Moore, James M. Nelson, Bill J. Roberts, Patrick W. Vincent, William A. Denny & Andrew M. Thompson. (1997)
Tyrosine Kinase Inhibitors. 6. Structure−Activity Relationships among
N
- and 3-Substituted 2,2‘-Diselenobis(1
H
-indoles) for Inhibition of Protein Tyrosine Kinases and Comparative
in Vitro
and
in Vivo
Studies against Selected Sulfur Congeners
. Journal of Medicinal Chemistry 40:4, pages 413-426.
Crossref
Crossref
Jürg Zimmermann, Elisabeth Buchdunger, Helmut Mett, Thomas Meyer & Nicholas B. Lydon. (1997) Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorganic & Medicinal Chemistry Letters 7:2, pages 187-192.
Crossref
Crossref
Glenda E. Bilder & Camilo J. Rojas. (2007) Inhibitors of the Platelet‐Derived Growth Factor Receptor Tyrosine Kinase. Cardiovascular Drug Reviews 14:4, pages 380-399.
Crossref
Crossref
Karsten Albrecht, Johannes Belzner, Alois Fürstner, Frank Bienewuld, Carsten Bolm, Thomas Ziegler, Klaus Frobel, Thomas Krämer, Ulrich Niewöhner & Stephan Schneider. (2010) Organische Chemie 1995. Nachrichten aus Chemie, Technik und Laboratorium 44:2, pages 147-167.
Crossref
Crossref
Peter M. Traxler, Pascal Furet, Helmut Mett, Elisabeth Buchdunger, Thomas Meyer & Nicholas Lydon. (1996) 4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase. Journal of Medicinal Chemistry 39:12, pages 2285-2292.
Crossref
Crossref
David W. Fry. 1996.
151
160
.